Primary atopic disorders (PAD) are monogenic disorders caused by pathogenic gene variants encoding proteins that are key for the maintenance of a healthy skin barrier and a well-functioning immune system. Physicians face the challenge to find single, extremely rare PAD patients/families among the millions of individuals with common allergic diseases. We describe case scenarios with signature PAD. We review the literature and deduct specific clinical red flags for PAD detection. They include a positive family history and/or signs of pathological susceptibility to infections, immunodysregulation, or syndromic disease. Results of conventional laboratory and most immunological lab studies are not sufficient to make a definitive diagnosis of PAD. In the past, multistep narrowing of differential diagnoses by various immunological and other laboratory tests led to testing of single genes or gene panel analyses, which was a time-consuming and often unsuccessful approach. The implementation of whole-genomic analyses in the routine diagnostics has led to a paradigm shift. Upfront genome-wide analysis by whole genome sequencing (WGS) will shorten the time to diagnosis, save patients from unnecessary investigations, and reduce morbidity and mortality. We propose a rational, clinical landmark-based approach for deciding which cases pass the filter for carrying out early WGS. WGS result interpretation requires a great deal of caution regarding the causal relationship of variants in PAD phenotypes and absence of proof by adequate functional tests. In case of negative WGS results, a re-iteration attitude with re-analyses of the data (using the latest data base annotation)) may eventually lead to PAD diagnosis. PAD, like many other rare genetic diseases, will only be successfully managed, if physicians from different clinical specialties and geneticists interact regularly in multidisciplinary conferences., Competing Interests: TN: Non-profit organizations (travel expenses, no fees): Jeffrey Modell Foundation (parent organization, donations from the industry); info4pi.org; PENTA Global Pediatric Research Network (with donations from industry); penta-id.org; JIR Cohort (research network with donations from industry); Publishers (royalties): UpToDate, Inc; Springer, Elsevier; Indirect interests (membership) Transparency International; Parents’ associations (children with cancer Krefeld, children’s cancer clinic Düsseldorf); SvH: None. Figure 1.Physiology of the normal skin/mucosa barrier (upper panel) and newborn of 37 + 6 weeks gestation with Netherton Syndrome (pathogenic variants in SPINK5): Ichthyosiform erythroderma with generalized scaling, severe cutaneous inflammation resulting in debilitating pruritus and extremely sensitive skin (lower panel, provided by Dr. Arpe, St. Marien Hospital, Düren, Germany). SPINK5 (serine protease inhibitor Kazal-type 5) encodes the multidomain serine protease inhibitor LEKTI (lymphoepithelial Kazal-type-related inhibitor), which controls the kallikrein network of the epidermis and regulates desmosome turnover. Desmosomes seal the keratinocyte network. Corneodesmosin (CDSN), Desmoglein1 (DSG1), or Desmoplakin (DSP) are key intercellular adhesion molecules. Filaggrin monomers contribute to epidermal water retention through their hygroscopic properties. Activation of Dectin 1 or IL17 receptor (IL17R) leads to activation of CARD14 and NFκB, important for keratinocyte homeostasis (upper panel from left to right).Figure 2A.Physiology of mast cell activation (left panel) and clinical images of an 8-year-old girl with PLCγ2-associated antibody deficiency and immune dysregulation (right panel; PLCG2 variant c.313G>A p.(Val10Ile), Department of Human Genetics, University of Göttingen) and urticaria on the right wrist after exposure to cooling (swimming pool) (above) and vesiculobullous eruptions on colder areas, knees (below). SCF is the primary growth factor for mast cells, KIT, the cognate receptor for SCF. EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2) is encoded by ADGRE2. Attachment to the membrane is mediated by a noncovalently bound subunit of the receptor, which activates EMR2/ADGRE2 in mast cells, when forcefully dissociated by physical shearing forces/mechanical stress (vibration), leading to degranulation. Phosphoinositide-specific phospholipase Cγ2 (PLCγ2) is important for B-cell differentiation and function. In mast cells, PLCγ2 is downstream of the IgE receptor and catalyzes the hydrolysis of phosphatidylinositol 4, 5-bisphosphate to the secondary messengers inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 induces the release of Ca2+ from the ER. PLCγ2 can be activated by cold temperature, which leads to spontaneous calcium flux and degranulation. Tryptase (TPSAB1) is present in mast cell secretory granules. α- and β-tryptases form tetramers stabilized by heparin and are released after degranulation, where they contribute to allergic inflammation, inducing pruritus (adapted from Carlberg and Velleuer. Molecular Immunology: How Science Works, Publisher, Springer International Publishing, 2022 and [6, 7, 8]).Figure 2B.Physiology of granulocyte NLRP3 inflammasome activation (left panel) and a 2-month-old boy with CINCA/NOMID (right panel; GOF variant in NLRP3; Institute for Clinical Chemistry, Ludwig Maximilian University, Munich, Germany) with continuous fever since birth, urticarial rash in changing locations (above), marked eosinophilia (up to 35,000/μL) and fast recovery after institution of IL1-blocking treatment (Anakinra) (below). The NLRP3 inflammasome is a multiprotein complex composed of NLRP3, adapter protein ASC, and protease caspase-1. Upon various stimuli (e.g., microbial ligands, crystals) NLRP3 inflammasome activates caspase‐1 to induce the release of proinflammatory IL1β (adapted from Carlberg and Velleuer. Molecular Immunology: How Science Works, Publisher, Springer International Publishing, 2022). Table 1.Other primary atopic diseases with disrupted epithelial and/or mucosal skin barrier [9, 10, 11]. DiseaseOMIM-PGeneInheritancePhenotypeFilaggrin deficiency#146700FLGAD or AR (LOF)– Ichthyosis vulgaris – Early-onset persistent atopic eczema – Elevated risk of food allergy and eczema herpeticumSevere dermatitis – multiple allergies – metabolic wasting syndrome (SAM)#615508DSG1; DSPAD or AR (LOF)– Life-threatening condition, severe dermatitis, multiple allergies, metabolic wasting – Hypotrichosis, palmoplantar hyperkeratosis, enamel defects, recurrent (skin) infections – In some patients little systemic involvement Peeling skin syndrome type B#270300CDSNAR (LOF)– Lifelong patchy peeling of the skin with chronic pruritus – Frequent food allergy, recurrent skin infections – Usually no failure to thriveCARD14 deficiency#602723CARD14AD (LOF)– Severe atopy, severe pyogenic and viral skin and respiratory tract infections due to impaired NFkB activation and impaired epidermal secretion of antimicrobial peptidesAD = autosomal dominant; AR = autosomal recessive; LOF = loss of function. Table 2.Other primary atopic disorders with dysregulated granulocyte / mast cell function [8, 13, 14]. DiseaseOMIM-PGeneInheritancePhenotypeCryopyrin-associated periodic syndromes (CAPS) composed of 1. Muckle-Wells syndrome 2. Familial cold autoinflammatory syndrome (FCAS1) 3. Neonatal onset multisystem inflammatory disease (NOMID) or chronic infantile neurologic cutaneous and articular syndrome (CINCA)#191900 #607115 #120100NLRP3AD (GOF)– Maculopapular, non-pruritic and most predominantly urticarial rashes – Arthritis, chills, fever and leukocytosis, e.g., after cold exposure (FCAS1) – Recurrent fever, musculoskeletal symptoms, abdominal and thoracic serositis, headache, ophthalmic and auditory nerve inflammation potentially leading to deafness and blindness preventable by IL1-directed treatment – Severity of symptoms variable between and within conditions, and not indicative of a particular diseaseNLRC4 or NLRP12-associated autoinflammatory diseases#616115 #611762NLRC4 NLRP12AD (GOF)Fever, arthritis/arthralgia, rash, abdominal pain, diarrhea, myalgia/fatigue and conjunctivitis triggered by cold exposureAD = autosomal dominant; GOF = gain of function. Figure 3.Central tolerance induction physiology (left panel) and neonate with Omenn syndrome and erythroderma (right panel, above) who was successfully treated by cord blood transplantation (below); (pictures kindly provided by H. Ott, Hannover, published in [16]). The thymic selection of T cells during the first decade of life produces millions of antigenically distinct T cells carrying a very diverse T-cell receptor (TCR) repertoire prepared to encounter millions of variants of microbial and other antigens. Some autoreactive T-cell clones are also generated. This selection process is called central tolerance induction. Figure 4.Physiology of Tregs (regulatory T cells) (left panel) and an infant with IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) (right panel, above). The patient presented with severe autoimmune enteropathy and growth charts showing failure to thrive, length and weight < 3rd percentile (right panel, below). Tregs induce peripheral tolerance, preventing development of autoimmune and allergic diseases. Their expression of the high affinity trimeric α/β/γ IL2 receptor (IL2R) helps them to selectively bind IL2 and draw it away from T effector cells (Teff) expressing only the low moderate affinity (β/γ) IL2R. FOXP3 is the lineage defining transcription factor for the development of Tregs. High levels of FOXP3 expression are directly linked to the suppressive capacity of Tregs. FOXP3 expression leads to the upregulation of the high affinity IL2 receptor as well as CTLA-4 on Tregs. CTLA-4 competes with the co-stimulatory molecule, CD28, for binding to CD80 and CD86 on antigen presenting cells (APCs). This is one other mechanism by which Tregs suppress immune responses. IKZF (IKAROS family zinc finger) have been shown to be critical for Treg and hematopoietic development. Table 3.Other primary atopic diseases Tregopathies [17, 18]. DiseaseOMIM-PGeneInheritancePhenotypeDisorders of Treg transcriptional programsIKAROS-associated (IKZF1) disease#616873IKZF1AD (GOF or LOF)– Onset > 1 to up to 40 years of age – Many present with atopic diseases – Autoimmunity/immune dysregulation can be profound: e.g. autoimmune cytopenias (Evans Syndrome), lymphoproliferation, plasma cell expansion (IgG4+), type 1 diabetes, thyroiditis alopecia, vitiligo, celiac disease, colitis) – Sinopulmonary infections – Expressivity of GOF variants is variable, asymptomatic individuals are commonDisorders of IL2 or CTLA4 signalingInterleukin 2 receptor a (IL2RA (CD25)) or interleukin-2 receptor β (IL2RB (CD122))#606367 #618495IL2RA (CD25), IL2RB (CD122)AR (LOF)IPEX-like (see above) and SCID-like presentations CTLA4 haploinsufficiency#152700CTLA4AD (LOF)Onset throughout childhood and adulthood. – Lymphoproliferation, lymphoma, gastric cancer, polyautoimmunity (e.g., autoimmune enteropathies, cytopenias, skin disease, interstitial lung disease, and neurologic manifestations). – Increased severity of infections (e.g., CMV, EBV). – Often initially diagnosed as CVID – Some parents and relatives with pathogenic variants asymptomatic.AD = autosomal dominant; AR = autosomal recessive; IPEX = immune dysregulation, polyendocrinopathy, enteropathy, X-linked; SCID = severe combined immunodeficieny; CMV = cytomegalovirus; EBV = Ebstein-Barr virus; CVID = common variable immunodeficiency. Table 4.Other defects in downstream TCR signalling, cytoskeleton activation and immune synapse formation [3, 19, 21, 22]. DiseaseOMIMGeneInheritancePhenotypeWiskott-Aldrich syndrome#301000WASXL (LOF)Onset: early childhood with the classic triad: – Thrombocytopenia (pathognomonic small mean platelet volume (< 5 fL)) – Recurrent severe infections (impetigo, cellulitis, skin abscesses, molluscum contagiosum; Herpesviruses, including herpes simplex and varicella-zoster virus, Epstein-Barr virus) – Eczema, often unresponsive to conventional treatment. – Early death may result from bleeding. – Autoimmunity and malignancy more common with increasing age. – Milder phenotype: X-linked thrombocytopenia without eczema or immunodeficiency.WIP deficiency#614493WIPF1AR (LOF)– WAS-like presentation, but very early onset of a severe immunodeficiencyNCKAP1L deficiency (HEM-1 hematopoietic protein 1)#618982NCKAP1LAR (LOF)– Atopic disease and hyperinflammation, chronic hepatosplenomegaly, lymphadenopathy – Recurrent fever and upper respiratory tract infections, skin rashes, abscesses, ulcers, autoimmune manifestations and FTTDOCK8 deficiency#243700DOCK8AR (LOF)– Extensive, disfiguring, concurrently occurring cutaneous viral infections, particularly HSV, human papillomavirus, molluscum contagiosum and varicella-zoster virus. – Invasive infections (wide spectrum of Gram-positive and Gram-negative bacteria, viruses and intracellular fungi, e.g., histoplasma capsulatum). – Mucocutaneous candidiasis and recurrent gastro-intestinal tract infections are common. – Severe and extensive food allergies. – High risk of developing malignancies, particularly lymphomas and squamous cell carcinomas. CARMIL2 (RLTPR) deficiency#618131CARMIL2AR (LOF)– Onset early infancy; – Atopic and seborrheic dermatitis and psoriasis-like rashes. – Viral (EBV, CMV, and varicella), bacterial, mycobacterial and fungal infections – Early or very early onset inflammatory bowel disease (VEOIBD) – Autoimmune polyendocrinopathy syndrome (APS) – Characteristic feature is EBV-associated leiomyoma (<20% of cases)STK4 deficiency#614868STK4AR (LOF)– Onset at school age – Infections (cutaneous viral infections, recurrent pneumonia, EBV-associated lymphoproliferation) – Autoimmune or inflammatory diseases and atopic dermatitis/atopyTBX21 deficiency (T-bet, T-box transcription factor 21) #619630TBX21AR (LOF)– Mendelian susceptibility to mycobacterial disease (MSMD) – Persistent upper airway inflammation Moesin-associated immunodeficiency (X-MAID)#300988MSNXLR (LOF) – Skin manifestations, mainly eczema, molluscum contagiosum and increased susceptibility to bacterial and viral infections and VEOIBDXL = X linked; LOF = loss of function; AD = autosomal dominant; AR = autosomal recessive; XLR = X-linked recessive; WAS = Wiscott-Aldrich syndrome; FTT = failure to thrive; HSV = Herpes simplex virus; EBV = Ebstein-Barr virus; CMV = cytomegalovirus; VEOIBD = very early onset inflammatory bowel disease. Figure 5.Physiology of the actin cytoskeleton (left panel) and a 3-year-old boy (right panel, above) with ARPC1B (actin related protein 2/3 complex subunit 1B) deficiency, presenting with ulcerating severe cutaneous viral infections (left shoulder and on the back) and after successful stem cell transplantation at 5 years of age (right panel, below). Rearrangement of actin cytoskeletons is key for immune cell activation, migration and adhesion. Human actin-related protein 2/3 complex (Arp 2/3) has ARPC1 component isoforms (ARPC1B, expressed in blood cells, ARPC1A in non-hematopoietic tissues). WASP (Wiskott Aldrich syndrome protein), WIPF1 (WASP interacting protein family member 1), DOCK8 (dedicator of cytokinesis 8), and NCKAP1 (Nck-associated protein 1 also called HEM1 (hematopoietic protein 1)). The RLTPR or CARMIL-2 protein, the TCR, and CD28 form microclusters that interact with actin and are key for the formation of the immunological synapse. Moesin (MSN) links actin filaments to the plasma membrane which increases cell rigidity and polarity and STK4 controls the translocation of vesicles to the surface and can activate actin (both not shown in Figure).Figure 6.Physiology of STAT3 signaling (left panel) and a 7-year-old boy with coarse facial features (right panel, above), eczema, cold skin abscesses (middle) and delayed dentition at 10 years of age (below, different patient). IL6 signals through the IL6RST (signal transducer of IL6 receptor complex), composed of glycoprotein 130 (GP130) and the IL6R. Other cytokines of the IL6 cytokine family utilize GP130 encoded by IL6ST (IL11, OSM, LIF, CNTF, CT-1, CLCF1, IL27, IL35, and IL39). IL6 then activates through JAK-STAT signal transduction the zinc finger protein 341 (ZNF341) TF, which promotes STAT3 transcription. IL6 and IL23 activate STAT3, which turns on RORC, encoding RORγt the master regulator for a TH1/TH17 T-cell response shift as well as chondrogenesis, bone repair, angiogenesis/vascularization (induction of vascular endothelial factor 3 (VEGF3)) [23]. The phosphoglucomutase 3 (PGM3) (not shown in figure) enzyme catalyzing the isomerization of N-acetyl-glucosamine-6-phosphate to N-acetyl-glucosamine-1-phosphate during the generation of UDP-N-acetyl-glucosamine UDP-GlcNAc. During glycosylation, sugar chains are added to either proteins or lipids, using basic sugar building blocks (UDP-GlcNAcs) to make N-glycans, O-glycans, proteoglycans, and glycosylphosphatidylinositol (GPI)-anchored proteins all participating in cell signaling. Table 5.PAD due to CBMopathies and cytokine signaling dysfunction [4, 7, 26]. DiseaseOMIMGeneInheritancePhenotypeCBMopathiesCARD11-associated atopy with dominant interference of the NFkB signaling (CADINS)#617638CARD11AD (LOF)– Very severe atopic dermatitis (close to 90% of cases) later followed by asthma and food allergy. Cutaneous viral and respiratory tract infections, potentially severe and causing FTT (e.g., due to diarrhea). Some patients display skeletal features as in STAT3 deficiency (broad nose, retained teeth).MALT1 deficiency#615468MALT1AR (LOF)– Left untreated it is thought to be fatal – Recurrent severe bacterial viral and fungal infections of the skin and/or respiratory and gastrointestinal tract infections, FTT – Periodontal disease, aphthous ulcers, cheileitis and gingivitis.TGFβ pathwayTransforming growth factor β receptor 1 and 2 (TGFBR 1 and 2) deficiency (Loeys-Dietz syndrome 1 and 2 )#609192 #610168TGFBR1, TGFBR2AD (LOF)– IgE-mediated food allergy, EGID, allergic asthma, and atopic dermatitis. Additional connective tissue abnormalities overlapping with those seen in STAT3 pathway disorders (hyperextensible joints, scoliosis, etc.)Erbb2-interacting protein (ERBIN) deficiencyNoneERBINAD (LOF)– Significant EGID, connective tissue abnormalities. – Enhanced TGF-β pathway activation leading to increased IL4Rα expression and enhanced Th2 differentiation and IgE productionJAK1/STAT5b pathwayJAK1 GOF#618999JAK1AD (GOF)– Severe atopic dermatitis and allergic asthma. Immune dysregulation such as autoimmunity (e.g., thyroid disease), poor growth, hepatosplenomegaly, eosinophilic enteritis. STAT5B hypereosinophilic syndrome#102578STAT5BSomatic (GOF) in multiple hematopoietic lineages– Neonatal onset dermatitis, urticarial rash and diarrhea, neonatal hypereosinophilia. – Patients with somatic GOF STAT5B variants have presented with leukemia and lymphomas.STAT5B deficiency#618985STAT5BAD (dominant negative) and AR (LOF)– Recurrent viral infections due to poor IL-2-mediated effector functions and chronic pulmonary disease (lymphocytic interstitial pneumonitis). – Extreme short stature due to the roles of STAT5b in growth factor signaling (Growth-hormone insensitive dwarfism, dysmorphic features). – Atopy, e.g., eczema. Prominent autoimmunity similar to IPEX (Modestly reduced Treg number and function). The AD form of STAT5B deficiency has growth-failure, eczema, but no immunodeficiency.IL4/STAT6 pathwaySTAT6-GOF disease (signal transducer and activator of transcription 6)#620532STAT6AD (GOF)– Severe early-onset, multi-system allergic disease, e.g. severe and treatment-resistant dermatitis, marked eosinophilic gastrointestinal disease. – Skin and respiratory infections as well as lymphadenopathy, cobblestone-like appearance of the buccal mucosa, polypoid nodules in the intestinal tract, and notably, B-cell lymphomas. – Non-immunological features: some resembling AD HIES, some are additional: renal fibrosis, short stature and hypotrichosisGOF = gain of function; LOF = loss of function; AD = autosomal dominant; AR = autosomal recessive; FTT = failure to thrive; EGID = eosinophilic gastrointestinal disease; IPEX = immune dysregulation, polyendocrinopathy, enteropathy, X-linked; HIES = hyper IgE syndrome . Table 6.Other primary atopic disorders with STAT3 dysfunction [4, 5, 6, 7, 24, 25]. DiseaseOMIMGeneInheritancePhenotypeZNF341 deficiency#618282ZNF341AR (LOF)– Phenocopy of AD-HIES Partial IL6 signal transducer (IL6ST) (GP130 deficiency)#619752IL6STAD (LOF)– Demonstrates phenotypic overlap with AD HIES but also diarrhea, keratitis, and neurodevelopmental delay. Complete IL6 signal transducer (IL6ST) (GP130 deficiency) #618523IL6STAR (LOF)– Death in utero or in neonatal period in most affected individuals. – Stuve-Wiedemann-like syndrome; skeletal dysplasia, osteoporosis, lung dysfunction, renal abnormalities, thrombocytopenia, eczema. IL6R deficiency#618944IL6RAR (LOF)– Atopic dermatitis, elevated IgE, bacterial sinopulmonary infection, and substantial skin and soft tissue infections – often due to staphylococcus. No connective tissue abnormalitiesPhosphoglucomutase 3 deficiency#615816PGM3AR (LOF) hypomorphic– Syndromic immunodeficiency due to glycosylation defect. Atopic dermatitis, bronchiectasis, and scoliosis but lack of characteristic AD HIES facies, chemotaxis defects, cold abscesses and connective tissue disease. – Developmental delay, primary neurocognitive deficits, hypomyelination and skeletal dysplasiaAD = autosomal dominant; AR = autosomal recessive; HIES = hyper IgE syndrome. Figure 7.A: CBM physiology CBM complexes are critical TCR signaling adapters. Antigen receptor stimulation leads to phosphorylation of CARD 11. Activated CARD 11 is recruited into the CBM complex to the ubiquitin regulatory proteins LUBAC and TRAF6 which ligate unique ubiquitin chains to BCL 10/MALT1 (not shown in Figure) and eventually lead to the activation of NFkB, JNK and ASCT2 regulating glutamine metabolism and activating MTOR. B: JAK1/STAT5/ TGFβ/STAT6 Physiology. TGFβ has roles in immune tolerance, cell cycle arrest, and wound healing. TGFβ signals through TGFBR1 and 2 Receptor. TGFβ increases IL4Rα expression and leads to T helper type 2 (TH2) differentiation and IgE production. ERBIN is a negative regulator of transforming growth factor (TGF)-signaling through interaction with SMAD proteins. STAT3 induces and then forms a complex with ERBIN. STAT5 is activated by signaling through receptors for various cytokines including IL2, hematopoietic growth factors, as well as growth hormone. STAT5B is an important regulator of FOXP3 expression, the essential TF for Tregs. STAT6 signaling induces activation of group 2 innate lymphoid cells (ILC2s), differentiation of TH2 cells from naïve CD4+ T cells and induction of T follicular helper (TFH) cells, which are crucial for B-cell affinity maturation and immunoglobulin class-switch recombination (CSR) in the germinal center. In non-immune cells, IL4/IL13 STAT6 is involved in collagen production of fibroblasts, the development of mucus-secreting goblet cells, eosinophil-attracting chemokine production from epithelial cells and induction of bronchial smooth muscle hyper-responsiveness.Table 7.Screening landmarks F, AD, ID, SY regarding history and physical findings. Presence of Red flags in > 2 landmarks will trigger whole genome analysis. Abnormal findings in lab investigations are only significant in presence of landmarks F, A, ID, SY. Land-markCategoryToolsRed FlagFFamily historyDraw a pedigree§, find inheritance pattern; know geographical distributions of consanguinity$– Presence of family members with IEI; family members fulfill other landmarks (see below)AAtopy disease history Get details: onset, extent, course– Onset: at birth/first 1 – 2 months of life – Extent: multiple simultaneous atopic manifestations such as severe asthma, life-threatening anaphylaxis, allergic rhinoconjunctivitis, multiple food allergies, eosinophilic esophagitis and gastroenteritis, protein-losing enteropathy – Course: very severe, not responsive to standard therapy IDImmunodeficiency, non-atopic past medical historyEvaluate pathological susceptibility to infections, signs of immunodysregulation, past medical history (ELVIS**, GARFIELD,** see next column)General– Failure to thrive+– Malignancy (e.g., lymphomas, leiomyosarcoma) Pathological susceptibility to infections (ELVIS)** – Unusual, opportunistic pathogens: e.g. pneumocystis – Localization: unusual, e.g., organ abscesses – Course: exceptionally long duration – Intensity: exceptionally severe, e.g., admission to intensive care unit. – Sum: Too many, e.g., in adults, >3 or in children > 6 infections per year which require treatment (including antibiotics) and each lasting more than 4 weeks Immunodysregulation (GARFIELD)** – Granuloma – Autoimmune disease – Recurring fever and chronic inflammation – Unusual eczema – Lymphoproliferation – Chronic, inflammatory bowel Disease SYSyndromic diseaseSkilled examination by experienced physician, clinical geneticist; supplementary use of artificial intelligence (next generation phenotyping (e.g., GestaltMatcher)++Key clinical findings such as hypotrichosis, neurodevelopmental delay, skeletal or connective tissue abnormalities (e.g., coarse facies, vascular anomalies, bleeding)! Caveat !: Except newborn SCID screening, results of conventional laboratory studies are not sufficient to make a definitive diagnosis of PAD. High levels of IgE or eosinophilia do occur in many PADs but are also common in non-primary allergic diseases. Abnormal findings in laboratory investigation count only as significant in the presence of landmarks F, A, ID, SY.LILab investigationsSCID newborn screening; full blood count; serum IgG, IgA, IgM, IgE; specific IgE panels to common aeroallergens and food allergens; Skin prick tests; urine glycans, serum tryptase; N- und O-glycosylation in serum transferrin electrophoresis, flow cytometry with immunodeficiency adapted markers; mast cell metabolites (e.g., histamine, leukotriens) in urine– Pathological TREC screening – Abnormal absolute numbers and relative percentages in full blood count (e.g., cytopenia; neutropenia, lymphopenia, thrombocytopenia, anemia) – Low IgG- SD age-adjusted; IgA < 5 mg/dL – Very high TH2 biomarkers: severe eosinophilia (>5,000 cells/mm3); serum total IgE > 2,000 kUIEI = inborn errors of immunity; SCID = severe combined immunodeficiency; PAD = primary atopic disease; TREC = T cell receptor excision circle;SD = standard deviation.&Online resources and instructions on How to Draw a Pedigree - Iowa Institute of Human Genetics (uiowa.edu); (Definition of pedigree - NCI Dictionary of Genetics Terms - NCI (cancer.gov); $Consang.net. **acronyms adapted from the German guideline for Diagnostics in Primary immunodeficiencies (S. Farmand, manuscript in preparation) and [31]; ELVIS = Erreger (pathogens), Lokalisation (localization), Verlauf (course), Intensität (intensity), Summe (sum); GARFIELD = Granulome (granuloma), Autoimmunität (autoimmunity), Rezidivierendes Fieber (recurrent fever), Darmentzündung (chronic inflammatory bowel disease). +Growth hormone evaluation and bone age study if there is short stature; delayed bone age and growth hormone deficiency may be found. ++www.db.gestatmatcher.org.Figure 8Rational, clinical landmark-based approach to identify patients/families with primary atopic disorders by early, upfront whole genome sequencing. If > 2 red flags are fulfilled, genetic analysis is indicated. In the following sections we discuss the different methods of genetic analysis and the cornerstones of genetic result interpretation in individuals with (suspected) primary atopic disorder. Details on red flags are given in Table 7., (© Dustri-Verlag Dr. K. Feistle.)